"repositioning the company into the usa" , page-5

A possible US listing is also how I am interpreting things.

"A product launch in the Rest of World requires western clinical studies (in addition to the Japanese trials) and the feasibility of Biota taking the product further into this process to capture greater value is well in hand."

To "capture greater value" Surely that is what we want!!

"Inavir represents a very different risk profile compared to previous Biota products at a similar stage of development and market entry. In addition, repositioning the Company into the USA and mechanisms by which that might occur are also amongst the options being considered within the current work program..."

Quotes from BTA's half yearly.

Based on what has been released a US listing could well be on the cards imo, in which case with Inavir already proven in Japan, BTA could skyrocket in price imo.